Harnessing AI and Genomics in Clinical Trial Enrollment
The Dana-Farber Cancer Institute (DFCI)’s MatchMiner tool was developed to increase historically low clinical trial enrollment rates in adults with cancer. Roy Perlis, MD, MSc, Editor in Chief of JAMA+ AI, spoke with Kenneth Kehl, MD, MPH, about his recent study published in JAMA Network Open evaluating the AI tool’s ability to fulfill its purpose through genome sequencing. Related Content: Clinical Trial Notifications Triggered by Artificial Intelligence–Detected Cancer Progression Considerations in Translating AI to Improve Care How AI Could Increase Clinical Trial Enrollment in Adults With Cancer
--------
15:09
--------
15:09
AI-Based Analysis for Parkinsonism
Delaying diagnosis of parkinsonism can mean delaying care. In a study recently published in JAMA Neurology, David Vaillancourt, PhD, and colleagues tested the ability of an AI model to differentiate between Parkinson disease and other neurodegenerative disorders when paired with MRI. He joins JAMA and JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH to discuss. Related Content: A Large Proportion of Parkinson Disease Diagnoses Are Wrong—Here’s How AI Could Help Automated Imaging Differentiation for Parkinsonism
--------
11:48
--------
11:48
Should Employers Offer Digital Mental Health Programs to Support Workforce Well-Being?
Employer-sponsored digital health solutions help patients with behavioral health conditions increase workplace productivity. Yulin Hswen, ScD, MPH, Associate Editor of JAMA+ AI, spoke with Molly Candon, PhD, and Adam Chekroud, PhD, about their recent work published in JAMA Network Open evaluating the financial return on investment for companies participating in these AI health care programs. Related Content: Employer-Sponsored Digital Health Platforms for Mental Wellness—A Good Investment Return on Investment of Enhanced Behavioral Health Services Return on Investment in Digital Mental Health Solutions
--------
21:55
--------
21:55
When Do Nudges Help?
Susan Athey, PhD, of Standford University joins JAMA+ AI Editor in Chief Roy H. Perlis, MD, MSc, to discuss her research on machine learning to target behavioral nudges for college students and their potential implications for health care. Related Content: How an Economist’s Application of Machine Learning to Target Nudges Applies to Precision Medicine
--------
21:35
--------
21:35
Real-World Performance of AI in Screening for Diabetic Retinopathy
Diabetic retinopathy remains a leading cause of preventable blindness worldwide, and AI may facilitate screening, if such models continue to perform well when they are deployed in the real world. Coauthors Arthur Brant, MD, of Stanford University, and Sunny Virmani, MS, of Google join JAMA+ AI Editor in Chief Roy H. Perlis, MD, MSc, to discuss a new study published in JAMA Network Open. Related Content: Diabetic Retinopathy Is Massively Underscreened—an AI System Could Help Performance of a Deep Learning Diabetic Retinopathy Algorithm in India
Discover the future of medicine with JAMA+ AI Conversations. This collection of interviews with clinicians, researchers, and AI experts explores how AI is impacting medicine – from clinical practice to training and research. Join us to uncover what lies ahead at the intersection of AI and medicine.
Portugal